Pervasis Therapeutics Secures $10M in New Financing

Xconomy Boston — 

Pervasis Therapeutics, a Cambridge, MA-based developer of drugs to heal blood vessels, has raised $10 million of a proposed $17.4 million round of private equity financing, according to an SEC filing. The startup names the prolific MIT inventor Bob Langer among its board members.

The SEC filing does not say who invested in the round, but Pervasis’s previous backers include Massachusetts venture firms Flagship Ventures, Highland Capital Partners, and Polaris Venture Partners, according to the firm’s website. This latest deal appears to be a Series C round of financing, based on the financial news that Pervasis has previously announced.

Luke took a more in-depth look at Pervasis’ technology when talked to company CEO Frederick Chereau, a former Genzyme (NASDAQ:GENZ) executive, last October. The company’s lead drug, Vascugel, is in clinical development to help repair of blood vessels in kidney disease patients who are on dialysis.